PRESS RELEASE: Doctors for America’s FDA Task Force Meet Legislators and Agency Officials

Doctors for America
PO Box 53313
1921 Florida Ave NW
Washington, DC  20009-9997

March 23, 2023

Doctors for America’s FDA Task Force Meet Legislators and Agency Officials

WASHINGTON, D.C. – This week Doctors for America’s Food and Drug Administration (FDA) Task Force is meeting with leaders on Capitol Hill to discuss patient-centered improvements to the FDA. The task force also attended and spoke at the Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting on March 22nd. 

Doctors for America’s FDA Task Force will share the feedback provided at the Advisory Committee meeting on ways to ensure that therapies approved by the FDA are safe, effective, and proven to show meaningful clinical benefit with both agency and Capitol Hill leaders. Physicians and patients rely on a robust FDA free of undue conflicts of interest. The FDA Task Force looks forward to working with policymakers to ensure FDA continues to serve as the “gold standard.”

In addition, the FDA Task Force will share with legislators that they filed an amicus brief in support of FDA’s approval of the use of mifepristone to end pregnancy through ten weeks gestation. Mifepristone has been proven safe and effective, with research showing that adverse events and outcomes are exceedingly rare, occurring in less than a fraction of 1% of cases. The full brief filed in the case of Alliance for Hippocratic Medicine v. FDA can be found here.

For press inquiries for members of the FDA Task Force Doctors for America please contact Claire Onyechi with Continuum Health Group ([email protected]).

About Doctors for America:

Doctors for America (DFA) mobilizes doctors and medical students to be leaders in putting patients over politics to improve the health of our patients, communities, and nation. DFA is an organization of over 27,000 physician and medical student advocates in all 50 states, representing all areas of specialization. DFA teaches physicians and medical students advocacy skills and does advocacy at a state and federal level. Our impact areas focus on access to affordable care, community health and prevention, and health justice and equity. DFA focuses solely on what is best for our patients, not on the business side of medicine, and does not accept any funding from pharmaceutical or medical device companies, which uniquely positions DFA as the organization that puts patients over politics and patients over profits.

Find out more at and on Twitter @drsforamerica.


Prescription Drugs, FDA